Виферон®

General characteristics. Structure:

Active ingredient: 150 000 ME, 500 000 ME, 1 000 000 ME or 3 000 000 ME of interferon alpha 2b human recombinant.

Excipients: alpha tocopherol acetate, ascorbic acid, sodium ascorbate, dinatrium эдетат dihydrate, polysorbate-80, basis cocoa butter and fat confectionery.

Pharmacological properties:

Pharmacodynamics. Interferon alpha 2b human recombinant has immunomodulatory, antiviral, anti-proliferative properties. Immunomodulatory properties of interferon, such as strengthening of phagocytal activity of macrophages, increase in specific cytotoxicity of lymphocytes to target cells cause its mediated antibacterial activity.

In the presence of ascorbic acid and alpha tocopherol of acetate specific antiviral activity of interferon increases, its immunomodulatory action amplifies that allows to increase efficiency of own immune response of an organism on pathogenic microorganisms. At use of drug the level of secretory immunoglobulins of a class A increases, immunoglobulin E level is normalized, there is a recovery of functioning of endogenous system of interferon. Ascorbic acid and alpha tocopherol acetate, being highly active antioxidants, possess antiinflammatory, membrane stabilizing, and also regenerating properties. It is established that at Viferon's use there are no side effects arising at parenteral administration of drugs of interferon the antibodies neutralizing antiviral activity of interferon are not formed.

Use of drug allows to lower therapeutic doses of antibacterial and hormonal medicines, and also to reduce toxic effects of the specified therapy.

Cocoa butter contains phospholipids which allow not to use synthetic toxic emulsifiers in production, and presence of polyunsaturated fatty acids facilitates introduction and dissolution of drug.

Indications to use:

— acute respiratory viral infections, including flu, including complicated by a bacterial infection, pneumonia (bacterial, virus, Chlamidia) at children and adults as a part of complex therapy;
— infectious and inflammatory diseases of newborn children, including premature: meningitis (bacterial, virus), sepsis, a pre-natal infection (clamidiosis, herpes, a Cytomegaloviral infection, an enteroviral infection, candidiasis, including visceral, mycoplasmosis) as a part of complex therapy;
— a chronic viral hepatitis of B, C, D at children and adults as a part of complex therapy, including in combination with use of a plasma exchange and hemosorption at the chronic viral hepatitis of the expressed activity complicated by cirrhosis;
— infectious and inflammatory diseases of an urogenital path (clamidiosis, a Cytomegaloviral infection, ureaplasmosis, trichomoniasis, a bacterial vaginosis, a human papillomavirus infection, the bacterial vaginosis recuring vulval candidiasis, mycoplasmosis) at adults as a part of complex therapy;
— primary or recurrent herpes infection of skin and mucous membranes, the localized form, an easy and medium-weight current, including an urogenital form at adults.

Route of administration and doses:

Drug is used rektalno. 1 suppository contains as active agent interferon alpha 2b human recombinant in the specified dosages (150000 ME, 500000 ME, 1000000 ME, 3000000 ME).

 • Acute respiratory viral infections, including flu, including complicated by a bacterial infection, pneumonia (bacterial, virus, Chlamidia) at children and adults as a part of complex therapy. The recommended dose for adults, including pregnant women and children is more senior than 7 years of ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 5 days. According to clinical indications therapy can be continued.

Including newborn and premature with gestational age more than 34 weeks, use of the drug ВИФЕРОН® 150000 ME on 1 suppository 2 times a day in 12 h daily within 5 days is recommended to children up to 7 years. According to clinical indications therapy can be continued. The break between courses makes 5 days.

Less than 34 weeks use of the drug ВИФЕРОН® 150000 ME on 1 suppository 3 times a day in 8 h daily within 5 days is recommended to premature newborn children with gestational age. According to clinical indications therapy can be continued. The break between courses makes 5 days.

 • Infectious and inflammatory diseases of newborn children, including premature: meningitis (bacterial, virus), sepsis, a pre-natal infection (clamidiosis, herpes, a Cytomegaloviral infection, an enteroviral infection, candidiasis, including visceral, mycoplasmosis) as a part of complex therapy. The recommended dose for newborn children, including premature with gestational age more than 34 weeks, ВИФЕРОН® 150000 ME daily on 1 suppository 2 times a day in 12 h. A course of treatment — 5 days.

Less than 34 weeks use of the drug ВИФЕРОН® 150000 ME daily on 1 suppository 3 times a day in 8 h is recommended to premature newborn children with gestational age. A course of treatment — 5 days.

The recommended quantity of courses at various infectious and inflammatory diseases: sepsis – 2-3 courses, meningitis — 1-2 courses, a herpes infection — 2 courses, an enteroviral infection — 1-2 courses, a Cytomegaloviral infection — 2 - 3 courses, mycoplasmosis, candidiasis, including visceral — 2-3 courses. The break between courses makes 5 days. According to clinical indications therapy can be continued.

 • A chronic viral hepatitis of B, C, D at children and adults as a part of complex therapy, including in combination with use of a plasma exchange and hemosorption at the chronic viral hepatitis of the expressed activity complicated by cirrhosis. The recommended dose for adults — ВИФЕРОН® 3000000 ME on 1 suppository 2 times a day in 12 h daily within 10 days, further three times a week in a day within 6-12 months. Duration of treatment is defined by clinical performance and laboratory indicators.

Aged up to 6 months it is recommended to children 300000-500000 ME in days; aged from 6 up to 12 months – 500000 ME in days.

It is recommended to children aged from 1 year up to 7 years 3000000 ME on 1 sq.m of surface area of a body a day.

To children 7 years are more senior it is recommended 5000000 ME on 1 sq.m of surface area of a body a day.

Drug is used by 2 times a day in 12 h the first 10 days daily, further three times a week every other day within 6-12 months. Duration of treatment is defined by clinical performance and laboratory indicators.

Calculation of a daily dose of drug for each patient is made by multiplication of the dose recommended for this age by the body surface area calculated according to the nomogram for calculation of surface area of a body on height and weight on Garforda, to Terry and Rourke. Calculation of a single dose is carried out by division of the calculated daily dose into 2 introductions, the received value round up to a suppository dosage.

At a chronic viral hepatitis of the expressed activity and cirrhosis before carrying out a plasma exchange and/or hemosorption use is recommended to children under 7 years of ВИФЕРОН® 150000 ME, to children 7 years of ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 14 days are aged more senior.

 • Infectious and inflammatory diseases of an urogenital path (clamidiosis, a Cytomegaloviral infection, ureaplasmosis, trichomoniasis, a bacterial vaginosis, a human papillomavirus infection, the bacterial vaginosis recuring vulval candidiasis, mycoplasmosis) at adults, including pregnant women as a part of complex therapy. The recommended dose for adults — ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 5-10 days. According to clinical indications therapy can be continued.

Use of the drug ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 10 days, then within 9 days 3 times at an interval of the 3rd day (for the fourth day) on 1 suppository 2 times a day in 12 hours is recommended to pregnant women from the II trimester of pregnancy (since 14th week of a gestation). Further each 4 weeks before delivery of ВИФЕРОН® 150000 ME on 1 suppository 2 times a day in 12 h daily within 5 days.

If necessary use of the drug ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 10 days is shown before delivery (from 38th week of a gestation).

 • Primary or recurrent herpes infection of skin and mucous membranes, the localized form, an easy and medium-weight current, including an urogenital form at adults, including pregnant women. The recommended dose for adults — ВИФЕРОН® 1000000 ME on 1 suppository 2 times a day in 12 h daily within 10 days and more at a recurrent infection. According to clinical indications therapy can be continued. It is recommended to begin treatment at once at emergence of the first signs of damages of skin and mucous membranes (an itch, burning, reddening).

At treatment of recurrent herpes it is desirable to begin treatment in a prodromal stage or at the very beginning of manifestation of signs of a recurrence.

Use of the drug ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 10 days, then within 9 days 3 times at an interval of the 3rd day (for the fourth day) on 1 suppository 2 times a day in 12 hours is recommended to pregnant women from the II trimester of pregnancy (since 14th week of a gestation). Further each 4 weeks before delivery of ВИФЕРОН® 150000 ME on 1 suppository 2 times a day in 12 h daily within 5 days. If necessary use of the drug ВИФЕРОН® 500000 ME on 1 suppository 2 times a day in 12 h daily within 10 days is shown before delivery (from 38th week of a gestation).

Dosing mode	Week of a gistation *				Scheme of use
Since the 14th week of a gestation of ВИФЕРОН® 500 000 ME on 1 suppository 2 times a day within 10 days. Further ВИФЕРОН® 500 000 ME on 1 suppository 2 times a day in 3 days, 3 times within 9 days.
Step 1. With + About (morning/evening) ВИФЕРОН® 500 000 ME	14	x	x	x	x	x	x	x
	15	x	x	x	x
	16	x				x
Further each 4 weeks to a rodrazresheniye of ВИФЕРОН® 150 000 ME on 1 suppository 2 times a day within 5 days.
Step 2. With + About (morning/evening) ВИФЕРОН® 150 000 ME	20, 24 28, 32 36, 40	x	x	x	x	x
Since the 38th week of a gestation to a rodrazresheniye of ВИФЕРОН® 500 000 ME on 1 suppository 2 times a day within 10 days.
With + About (morning/evening) ВИФЕРОН® 500 000 ME	38	x	x	x	x	x	x	x
	39	x	x	x
	40

Features of use:

Influence on ability to manage vehicles and to be engaged in other types of activity. It is not established.

Use at pregnancy and during breastfeeding: Drug is allowed for use from 14th week of pregnancy. Has no restrictions to use during breastfeeding.

Side effects:

Development of allergic reactions (skin rashes, itch) is in rare instances possible. These phenomena are reversible and disappear in 72 h after the termination of administration of drug.

Interaction with other medicines:

ВИФЕРОН®, suppositories rectal, we will combine and it is well combined with all medicines used at treatment of the above-stated diseases (antibiotics, himiopreparata, glucocorticosteroids).

Contraindications:

Hypersensitivity to any of drug components.

Overdose:

It is not established.

Storage conditions:

At a temperature from 2 to 8 °C, in the place protected from light. To store in the places unavailable to children. A period of validity - 2 years. Not to use drug after a period of validity.

Issue conditions:

Without recipe

Packaging:

Suppositories rectal 150000 ME, 500000 ME, 1000000 ME, 3000000 ME. On 5 or 10 suppositories in a PVC/PVC blister strip packaging. 1 blister strip packaging on 10 suppositories or 2 blister strip packagings on 5 suppositories with the application instruction in a pack from a cardboard.